CA2130563A1 - Derive de 2,6-methano-2h-qinolizine, antagoniste du recepteur 5-ht3 - Google Patents

Derive de 2,6-methano-2h-qinolizine, antagoniste du recepteur 5-ht3

Info

Publication number
CA2130563A1
CA2130563A1 CA 2130563 CA2130563A CA2130563A1 CA 2130563 A1 CA2130563 A1 CA 2130563A1 CA 2130563 CA2130563 CA 2130563 CA 2130563 A CA2130563 A CA 2130563A CA 2130563 A1 CA2130563 A1 CA 2130563A1
Authority
CA
Canada
Prior art keywords
treatment
quinolizin
receptor antagonist
methano
derivative
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
CA 2130563
Other languages
English (en)
Other versions
CA2130563C (fr
Inventor
Maurice W. Gittos
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Aventis Pharmaceuticals Inc
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA2130563A1 publication Critical patent/CA2130563A1/fr
Application granted granted Critical
Publication of CA2130563C publication Critical patent/CA2130563C/fr
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
    • C07D471/18—Bridged systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/26—Psychostimulants, e.g. nicotine, cocaine

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Hospice & Palliative Care (AREA)
  • Otolaryngology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
CA002130563A 1992-02-24 1993-02-03 Derive de 2,6-methano-2h-qinolizine, antagoniste du recepteur 5-ht3 Expired - Lifetime CA2130563C (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP92400474.0 1992-02-24
EP92400474 1992-02-24

Publications (2)

Publication Number Publication Date
CA2130563A1 true CA2130563A1 (fr) 1993-09-02
CA2130563C CA2130563C (fr) 1997-11-11

Family

ID=8211614

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002130563A Expired - Lifetime CA2130563C (fr) 1992-02-24 1993-02-03 Derive de 2,6-methano-2h-qinolizine, antagoniste du recepteur 5-ht3

Country Status (14)

Country Link
EP (1) EP0628043A1 (fr)
JP (1) JPH07504192A (fr)
KR (1) KR100287933B1 (fr)
AU (1) AU675060B2 (fr)
CA (1) CA2130563C (fr)
FI (1) FI105917B (fr)
HU (1) HU216831B (fr)
IL (1) IL104821A (fr)
MX (1) MX9300948A (fr)
NO (1) NO943101D0 (fr)
NZ (1) NZ249346A (fr)
TW (1) TW226374B (fr)
WO (1) WO1993017019A1 (fr)
ZA (1) ZA931146B (fr)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000048597A1 (fr) 1999-02-18 2000-08-24 Novartis Ag Utilisation systemique d'antagonistes du recepteur 5-ht3 contre des processus inflammatoires rhumatismaux
US8524731B2 (en) 2005-03-07 2013-09-03 The University Of Chicago Use of opioid antagonists to attenuate endothelial cell proliferation and migration
ES2714198T3 (es) 2005-03-07 2019-05-27 Univ Chicago Uso de antagonistas opioideos para atenuar la proliferación y la migración de células endoteliales
US8518962B2 (en) 2005-03-07 2013-08-27 The University Of Chicago Use of opioid antagonists
US9662325B2 (en) 2005-03-07 2017-05-30 The University Of Chicago Use of opioid antagonists to attenuate endothelial cell proliferation and migration

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0329932B1 (fr) * 1988-02-23 1995-10-18 Merrell Pharmaceuticals Inc. Utilisation des dérivés de la quinolizine et de la quinolizinone pour la manufacture des médicaments
EP0517984A1 (fr) * 1991-06-11 1992-12-16 Merrell Dow Pharmaceuticals Inc. Derivés d'analogues d'amide de quinolizines à pont méthano

Also Published As

Publication number Publication date
IL104821A0 (en) 1993-06-10
NO943101L (no) 1994-08-23
MX9300948A (es) 1993-08-01
AU675060B2 (en) 1997-01-23
WO1993017019A1 (fr) 1993-09-02
EP0628043A1 (fr) 1994-12-14
NZ249346A (en) 1995-10-26
HU216831B (hu) 1999-09-28
IL104821A (en) 1997-01-10
FI943872L (fi) 1994-08-23
FI105917B (fi) 2000-10-31
ZA931146B (en) 1993-09-14
CA2130563C (fr) 1997-11-11
FI943872A0 (fi) 1994-08-23
HUT68249A (en) 1995-06-28
KR100287933B1 (ko) 2001-05-02
KR950700297A (ko) 1995-01-16
HU9402436D0 (en) 1994-10-28
AU3603493A (en) 1993-09-13
NO943101D0 (no) 1994-08-23
JPH07504192A (ja) 1995-05-11
TW226374B (fr) 1994-07-11

Similar Documents

Publication Publication Date Title
SI0725779T1 (fr)
CA2149242A1 (fr) Derive de la quinuclidine pour le traitement de troubles inflammatoires et gastro-intestinaux
WO2000035919A3 (fr) Composes
CA2182981A1 (fr) Composition pharmaceutique sublinguale ou buccale
HUP9701096A3 (en) Use of benzenesulfonamides for the preparation of pharmaceutical compositions treating disorders of the central nervous system, novel derivatives, process for their preparation and pharmaceutical compositions containing them
IE891798L (en) Novel ó-glucosidase inhibitors
HU9502588D0 (en) Heterocyclic compounds and their preparation and use
AU1877495A (en) Naphthylamides as central nervous system agents
UA70919C2 (uk) Композиція для лікування та запобігання артеріальному тромбозу з використанням інгібітора фактора ха окремо або в комбінації з препаратом, що унеможливлює агрегацію тромбоцитів
CA2094702A1 (fr) Derives de substitution de tetrahydropyridines et d'hydroxypiperidines, agents therapeutiques pour le systeme nerveux central
CA2139385A1 (fr) Produits renfermant une proteine liante de g-csf et de tnf
EP1032556A4 (fr) Composes pharmaceutiquement actifs et procedes d'utilisation
WO1996023769A3 (fr) Composes heterocycliques possedant une activite antagoniste vis-a-vis du recepteur de 5ht¿2c?
CA2275167A1 (fr) Utilisation locale d'agonistes opioides kappa dans le traitement de la douleur oculaire
CA2282279A1 (fr) Atropisomeres de 3-heteroaryl-4(3h)-quinazolinones pour le traitement des troubles neurodegeneratifs et des troubles lies a un traumatisme du systeme nerveux central
CA2130563A1 (fr) Derive de 2,6-methano-2h-qinolizine, antagoniste du recepteur 5-ht3
AU6428294A (en) Imidazoloquinoxalinone derivatives as eaa antagonists
AU1604592A (en) New 2-amino-5-cyano-1,4-dihydropyridines, processes for their preparation and their use in medicaments
CA2235951A1 (fr) Nouveaux emplois du ctla-8 de mammifere et reactifs associes
WO2000006575A3 (fr) Nouveaux composes
AU3360000A (en) Use of 4-amino pyridine for treatment of peripheral neuropathies
CA2269031A1 (fr) Traitement de l'incontinence d'urine et compositions a cet usage
CA2149766A1 (fr) Compositions a base de flunisolide pour application rectale servant au traitement des troubles inflammatoires de l'intestin
AU686976B2 (en) Isopropyl 2-methoxyethyl 4-(2-chloro-3-cyano-phenyl)-1, 4-dihydro-2,6-dimethyl-pyridine-3,5-dicarboxylate
CA2180155A1 (fr) Naphtylamides comme agents actifs sur le systeme nerveux central

Legal Events

Date Code Title Description
EEER Examination request
MKEX Expiry

Effective date: 20130204